Bernstein analyst William Pickering initiated coverage of Alnylam with an Outperform rating and $243 price target. The firm is "big believers" in the ATTR Amyloidosis growth story. Despite the recently announced FDA advisory committee meeting, the analyst expects to see Onpattro approved for the cardiomyopathy indication of ATTR Amyloidosis by end of year.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ALNY:
- Alnylam and Medison Pharma expand multi-regional partnership to Eastern Europe
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- Alnylam price target lowered to $291 from $310 at Canaccord
- Alnylam price target lowered to $265 from $270 at Citi
- SVB downgrades Moderna to Underperform as COVID boom reverses
